Deptartment Hematology, Oncology, Westpfalz-Klinikum Kaiserslautern, Kaiserslautern, Germany
Hartmut Link , Josef Nietsch , Markus Kerkmann , Petra Angelika Ortner
Background: Primary G-CSF prophylaxis after chemotherapy is recommended in evidence based guidelines (GL), if the risk of febrile neutropenia (FN) is high (≥20%), or intermediate (≥ 10% - 20%) in case of risk factors. The aim was to evaluate, if G-CSF is used as proposed by GL, to identify determinants of GL implementation and adherence. Methods: The sample size was calculated at 2% of the incidence of malignant lymphoma, breast and lung cancer in Germany. Pts who had received 3-9 cycles of chemotherapy with a FN risk ≥10% between 5/2011 to 4/2012 were documented retrospectively. Results: 286 lymphoma, 666 lung cancer and 976 breast cancer pts were collected from 87 hospitals and 59 oncology practices with 195 physicians participating. Adherence to GL was higher in physicians up to 10 than over 10 years of experience. Conclusions: The adherence to and acceptance of GL for G-CSF may not be sufficient. Patient risk factors are underestimated therefore resulting in a possible underuse of G-CSF. Physicians may underestimate FN risk in pts who have an intermediate risk of FN and they overestimate their adherence to the GL.
Lymphoma pts % |
Lung cancer pts % |
Breast cancer pts % |
||
---|---|---|---|---|
Comorbidity | 18,2 | 39,2 | 14,8 | |
Adherence to GL | FN high-risk chemotherapy 1st/2nd/3rd cycles |
82,4/ 77,8/ 82,9 | 11,1/ 13,3/ 15,5 | 72,6/ 77,4/ 78,3 |
FN intermediate risk chemotherapy 1st/2nd/3rd cycles |
71,2/ 67,9/ 70,8 | 26,8/ 29,3/ 31,2 | 69,3/ 69,9/ 71,5 | |
Reasons not to use G-CSF in 1st cycle of high-risk chemotherapy |
||||
No additional risk factors for FN | 51,9 | 39,5 | 65,1 | |
Individual decision | 33,3 | 21,1 | 22,1 | |
FN-risk low by own experience | 14,8 | 15,7 | 24,4 | |
G-CSF as secondary prophylaxis | 11,1 | 19,5 | 12,8 | |
G-CSF only in FN-risk ≥ 40% | 11,1 | 1,1 | 15,1 | |
Institutions' decision | 3,7 | 9,7 | 8,1 | |
Reasons not to use G-CSF in 1st cycle of intermediate-risk chemotherapy |
||||
No additional risk factors for FN | 44,6 | 51,6 | 64,7 | |
Individual decision | 38,5 | 4,9 | 18,3 | |
FN-risk low by own experience | 18,5 | 21,0 | 29,7 | |
G-CSF as secondary prophylaxis | 9,2 | 14,2 | 16,3 | |
G-CSF only in FN-risk ≥ 40% | 1,5 | 1,4 | 8,0 | |
Institutions' decision | 10,8 | 9,6 | 6,7 | |
In principle no G-CSF | 7,7 | 16,4 | 5,6 | |
Chemotherapy cycles % | ||||
Physicians compliance with the EORTC G-CSF GL in high/intermediate FN-risk | 84,2/68,9 | 13,9/27,3 | 76,3/67,6 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Genitourinary Cancers Symposium
First Author: Nely Mercy Diaz Mejia
2021 ASCO Quality Care Symposium
First Author: Jaime Shaw
2022 ASCO Annual Meeting
First Author: Douglas W. Blayney
2024 ASCO Annual Meeting
First Author: Grace B Gallagher